Clinical Trials for Prinicipal Investigator: Ritesh Parajuli

3 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-17-05 Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing Open
UCI-18-02 A Phase II, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients with Early Triple-Negative Breast Cancer Open
UCI-18-06 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment Open